Ignite Creation Date:
2024-05-05 @ 5:04 PM
Last Modification Date:
2024-10-26 @ 9:28 AM
Study NCT ID:
NCT00384423
Status:
COMPLETED
Last Update Posted:
2008-01-30
First Post:
2006-10-04
Brief Title:
Short Term Effects of PRX-03140 in Patients With Mild Alzheimers Disease Being Treated With Aricept
Sponsor:
Epix Pharmaceuticals Inc
Organization:
Epix Pharmaceuticals Inc
Study Overview
Official Title:
A Randomized Double-Blind Placebo-Controlled Phase IIa Study to Assess the Short-Term Effects of PRX-03140 Alone and in Combination With Donepezil in Subjects With Mild Alzheimers Disease
Status:
COMPLETED
Status Verified Date:
2008-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a study to evaluate the safety tolerability pharmacokinetics and pharmacodynamics of PRX-03140 administered orally once daily for 14 days in subjects with mild Alzheimers Disease who are using a stable well-tolerated 10 mg dose of Aricept donepezil but continue to experience worsening AD symptoms
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None